title: Diffuse large B-cell lymphoma in adults aged 75 years and older: a single institution analysis of cause-specific survival and prognostic factors.
abstract: BACKGROUND
  Very elderly patients (75 years and older) with diffuse large B-cell lymphoma (DLBCL) will be increasingly considered for cancer treatment as the population ages, but are underrepresented in clinical trials. Here we report outcomes of very elderly DLBCL patients treated in the modern era at the Oregon Health and Science University (OHSU).
  
  
  METHODS
  We queried the OHSU Tumor Registry for DLBCL cases treated since 2002. A total of 73 patients aged 75 years or older were analyzed under Institutional Review Board approval.
  
  
  RESULTS
  With a median follow up of 31 months, cause-specific survival was 58% and overall survival 51% at 3 years. Incorporation of an anthracycline did not influence outcomes. More than one extranodal site or poor-risk disease by Revised International Prognostic Index score were adversely prognostic, but pathologic features studied were not.
  
  
  CONCLUSIONS
  Very elderly patients with DLBCL require prospective studies, which employ novel risk stratification and therapeutic approaches.
authors: Department of Medicine, Division of Medical Oncology, University of Washington, 825 Eastlake Avenue E, G3-200, Seattle, WA 98109-1023, USA.
authors: Stephen D
authors: SD
authors: Smith
authors: Andy
authors: A
authors: Chen
authors: Stephen
authors: S
authors: Spurgeon
authors: Craig
authors: C
authors: Okada
authors: Guang
authors: G
authors: Fan
authors: Jennifer
authors: J
authors: Dunlap
authors: Rita
authors: R
authors: Braziel
authors: Richard
authors: R
authors: Maziarz
keywords: DLBCL; elderly; prognosis